Global MASH Drug Market Growth (Status and Outlook) 2026-2032
The global MASH Drug market size is predicted to grow from US$ 1028 million in 2025 to US$ 5702 million in 2032; it is expected to grow at a CAGR of 22.2% from 2026 to 2032.
MASH Drug refers to pharmacological therapies developed for metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory and fibrotic form of metabolic dysfunction-associated steatotic liver disease (MASLD), historically referred to as NASH. The research scope focuses on disease-modifying therapies intended to improve steatohepatitis activity, reduce or reverse liver fibrosis, or modify metabolic and fibrotic pathways associated with disease progression. The market covers approved products and investigational candidates across oral, subcutaneous and intravenous administration, and across small-molecule, peptide/protein, RNA or oligonucleotide, carbohydrate-based and other therapeutic modalities.
Key Findings
The average gross profit margin of this product is 72%
Two FDA-approved therapies establish a commercial MASH treatment market
F2-F3 noncirrhotic disease remains the core approved treatment population
Oral small molecules and injectable therapies define current modality competition
F4 cirrhosis remains an important late-stage development opportunity
Pipeline competition spans metabolic antifibrotic and gene-silencing mechanisms
Market Trends
The MASH Drug market is moving from a predominantly clinical-development market toward a multi-mechanism commercial treatment category. The first stage of commercialization has been led by liver-directed THR-? therapy and GLP-1 therapy, while the development pipeline is broadening toward agents that address both hepatic pathology and systemic cardiometabolic dysfunction. This is particularly relevant because MASH commonly overlaps with obesity, type 2 diabetes and other metabolic risk factors. The next competitive phase is therefore likely to emphasize the balance between fibrosis improvement, MASH resolution, weight and metabolic benefits, dosing convenience and long-term safety rather than a single histological endpoint. At the same time, late-stage programs involving FGF21 analogs, GLP-1/glucagon dual agonists, pan-PPAR agonists and other mechanisms are increasing the potential for differentiated treatment selection and future combination strategies. Gene-silencing approaches targeting genetically validated liver pathways further broaden the longer-term technology landscape.
Market Dynamics
Drivers
The primary demand driver is the close relationship between MASH and the expanding cardiometabolic patient population. Obesity, type 2 diabetes and related metabolic abnormalities increase the pool of patients requiring fibrosis assessment and long-term liver disease management, while the emergence of approved pharmacotherapy is giving physicians a clearer reason to identify patients before progression to cirrhosis. The approvals of resmetirom and semaglutide have also validated two distinct therapeutic approaches, strengthening clinical awareness of pharmacological intervention for F2-F3 disease. As treatment options expand, referral pathways between hepatology, gastroenterology, endocrinology and metabolic-care settings are expected to become increasingly important to market development.
Restraints
The major restraint is that commercial treatment depends on accurately identifying patients with clinically meaningful fibrosis from a much broader population with metabolic liver disease. Current approved indications remain concentrated in noncirrhotic patients with moderate-to-advanced fibrosis, limiting immediate addressability compared with the overall MASLD population. In addition, accelerated or conditional approvals require continued generation of confirmatory clinical evidence, making long-term outcomes, treatment persistence and real-world effectiveness important factors for payer and physician confidence. Chronic treatment duration, medication access and the need to coordinate liver and metabolic management may also constrain penetration even where eligible patients are identified.
Opportunities
The most significant expansion opportunity lies beyond the current F2-F3 treatment core. Compensated MASH cirrhosis represents an important unmet segment, with several development programs evaluating therapies in F4 disease or portal-hypertension-related populations. A second opportunity is combination therapy, in which agents acting on liver fibrosis or de novo lipogenesis could potentially be paired with established or emerging metabolic therapies. In parallel, RNAi programs targeting HSD17B13, PNPLA3 and CIDEB introduce a genetically informed therapeutic strategy that may eventually create new treatment segments beyond conventional receptor agonists and metabolic small molecules. These approaches increase the possibility that future MASH treatment will become stratified by fibrosis stage, metabolic phenotype and molecular mechanism.
Challenges
The main industry challenge is demonstrating durable differentiation in a rapidly expanding pipeline. Future candidates will increasingly be compared not only on MASH resolution or fibrosis improvement, but also on cardiometabolic benefits, safety, tolerability, route of administration and suitability for chronic therapy. Developers must also address the commercial difficulty of translating clinical-trial eligibility into routine diagnosis and treatment, particularly when patients are managed across multiple specialties. For clinical-stage companies, increasingly large late-stage studies and confirmatory requirements raise development costs and financing demands, while the arrival of approved therapies raises the efficacy and convenience benchmarks that new entrants must meet.
Industry Chain Analysis
The MASH Drug industry chain begins with pharmaceutical raw materials, active pharmaceutical ingredients, specialty intermediates and modality-specific manufacturing technologies. Small-molecule programs depend on chemical synthesis and formulation capabilities, while peptide and protein therapies require biologic or peptide production systems, and RNA/oligonucleotide therapies require sequence design, oligonucleotide synthesis, conjugation and liver-targeted delivery technologies. In the midstream, value creation is concentrated in target validation, candidate selection, clinical development, fibrosis and metabolic endpoint demonstration, regulatory approval, scale-up manufacturing and lifecycle management. Because MASH is a chronic disease with heterogeneous metabolic and fibrotic characteristics, the ability to generate evidence across both liver-specific and cardiometabolic outcomes is becoming increasingly valuable. Downstream commercialization involves hepatology and gastroenterology practices, metabolic and obesity-care networks, specialty pharmacy channels and healthcare systems. Market value therefore depends not only on drug efficacy, but also on patient identification, fibrosis staging, reimbursement access, treatment persistence and the ability to integrate therapy into multidisciplinary chronic-disease management.
Segment Insights
By mechanism, THR-? agonists and GLP-1 receptor agonists currently represent the most commercially advanced MASH Drug segments because each class now has an FDA-approved therapy for moderate-to-advanced fibrosis. Beyond these categories, the pipeline remains highly diversified. FGF21 analogs, GLP-1/glucagon dual receptor agonists and pan-PPAR agonists are positioned around combined liver and metabolic effects, while FASN inhibitors and galectin-3 inhibitors focus more directly on pathways associated with lipid synthesis, fibrogenesis or advanced disease. RNA and oligonucleotide approaches provide an additional mechanism layer through genetically linked targets.
From a product-form perspective, oral therapies have an important convenience advantage for long-term chronic management, while injectable peptide/protein drugs can leverage strong metabolic efficacy and established treatment behavior in obesity and diabetes. From a development-status perspective, approved MASH drugs currently represent a relatively concentrated segment, whereas investigational candidates remain much broader in both mechanism and modality. From a patient perspective, F2-F3 noncirrhotic MASH is the principal commercial treatment segment today, while F4 compensated cirrhosis is becoming one of the most strategically important development areas.
Downstream Market Opportunities
The downstream opportunity is increasingly defined by patient phenotype rather than liver disease alone. Patients with F2-F3 fibrosis remain the core pharmacological treatment population, but MASH patients with obesity or type 2 diabetes create a particularly important overlap between hepatology and metabolic medicine. Therapies capable of addressing liver disease together with weight, glycemic or broader cardiometabolic risk factors may therefore have advantages in multidisciplinary treatment pathways. At the other end of the disease spectrum, patients with compensated cirrhosis represent a high-unmet-need population and an important extension opportunity for antifibrotic, metabolic and combination approaches if ongoing development programs establish sufficient clinical benefit.
Regional Insights
North America is currently the most commercially advanced MASH Drug region. The United States established the first dedicated pharmacological treatment market with FDA approval of Rezdiffra in March 2024 and subsequently broadened mechanism choice through approval of Wegovy for MASH in August 2025. This early regulatory transition has placed the U.S. at the center of initial physician adoption, patient-identification practices and commercial access development.
Europe entered the commercialization stage after Rezdiffra received conditional European Union marketing authorization in August 2025, with rollout occurring on a country-by-country basis. The regional market is therefore moving from clinical development toward commercial access, although reimbursement structures and launch timing can vary across countries. In other regions, future market development will depend more strongly on local regulatory approvals, fibrosis-diagnosis capacity, reimbursement systems and the ability to identify high-risk patients within large obesity and type 2 diabetes populations.
Competitive Landscape Analysis
The competitive landscape is shifting from a single-product market toward a layered structure combining commercial products, late-stage metabolic therapies, liver-targeted small molecules and genetically directed treatments. Madrigal Pharmaceuticals established the first-mover position with Rezdiffra, while Novo Nordisk introduced a GLP-1-based treatment route through Wegovy. Roche is building a late-stage FGF21 position around pegozafermin, and Boehringer Ingelheim, Inventiva and Altimmune are advancing survodutide, lanifibranor and pemvidutide through late-stage development. Viking Therapeutics provides additional THR-? competition through VK2809, while Alnylam Pharmaceuticals and Regeneron Pharmaceuticals are pursuing gene-silencing programs against HSD17B13, PNPLA3 and CIDEB. Galectin Therapeutics is differentiated by its focus on belapectin for MASH cirrhosis and portal hypertension, whereas Sagimet Biosciences is developing the FASN inhibitor denifanstat and exploring combination development with resmetirom. The strategic direction of competition is therefore moving beyond simple entry into MASH toward mechanism differentiation, fibrosis-stage expansion, metabolic benefit and potential combination positioning.
Report Scope
LPI (LP Information)' newest research report, the “MASH Drug Industry Forecast” looks at past sales and reviews total world MASH Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected MASH Drug sales for 2026 through 2032. With MASH Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world MASH Drug industry.
This Insight Report provides a comprehensive analysis of the global MASH Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on MASH Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global MASH Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for MASH Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global MASH Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of MASH Drug market by product type, application, key players and key regions and countries.
Market Segmentation
MASH Drug refers to pharmacological therapies developed for metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory and fibrotic form of metabolic dysfunction-associated steatotic liver disease (MASLD), historically referred to as NASH. The research scope focuses on disease-modifying therapies intended to improve steatohepatitis activity, reduce or reverse liver fibrosis, or modify metabolic and fibrotic pathways associated with disease progression. The market covers approved products and investigational candidates across oral, subcutaneous and intravenous administration, and across small-molecule, peptide/protein, RNA or oligonucleotide, carbohydrate-based and other therapeutic modalities.
Key Findings
The average gross profit margin of this product is 72%
Two FDA-approved therapies establish a commercial MASH treatment market
F2-F3 noncirrhotic disease remains the core approved treatment population
Oral small molecules and injectable therapies define current modality competition
F4 cirrhosis remains an important late-stage development opportunity
Pipeline competition spans metabolic antifibrotic and gene-silencing mechanisms
Market Trends
The MASH Drug market is moving from a predominantly clinical-development market toward a multi-mechanism commercial treatment category. The first stage of commercialization has been led by liver-directed THR-? therapy and GLP-1 therapy, while the development pipeline is broadening toward agents that address both hepatic pathology and systemic cardiometabolic dysfunction. This is particularly relevant because MASH commonly overlaps with obesity, type 2 diabetes and other metabolic risk factors. The next competitive phase is therefore likely to emphasize the balance between fibrosis improvement, MASH resolution, weight and metabolic benefits, dosing convenience and long-term safety rather than a single histological endpoint. At the same time, late-stage programs involving FGF21 analogs, GLP-1/glucagon dual agonists, pan-PPAR agonists and other mechanisms are increasing the potential for differentiated treatment selection and future combination strategies. Gene-silencing approaches targeting genetically validated liver pathways further broaden the longer-term technology landscape.
Market Dynamics
Drivers
The primary demand driver is the close relationship between MASH and the expanding cardiometabolic patient population. Obesity, type 2 diabetes and related metabolic abnormalities increase the pool of patients requiring fibrosis assessment and long-term liver disease management, while the emergence of approved pharmacotherapy is giving physicians a clearer reason to identify patients before progression to cirrhosis. The approvals of resmetirom and semaglutide have also validated two distinct therapeutic approaches, strengthening clinical awareness of pharmacological intervention for F2-F3 disease. As treatment options expand, referral pathways between hepatology, gastroenterology, endocrinology and metabolic-care settings are expected to become increasingly important to market development.
Restraints
The major restraint is that commercial treatment depends on accurately identifying patients with clinically meaningful fibrosis from a much broader population with metabolic liver disease. Current approved indications remain concentrated in noncirrhotic patients with moderate-to-advanced fibrosis, limiting immediate addressability compared with the overall MASLD population. In addition, accelerated or conditional approvals require continued generation of confirmatory clinical evidence, making long-term outcomes, treatment persistence and real-world effectiveness important factors for payer and physician confidence. Chronic treatment duration, medication access and the need to coordinate liver and metabolic management may also constrain penetration even where eligible patients are identified.
Opportunities
The most significant expansion opportunity lies beyond the current F2-F3 treatment core. Compensated MASH cirrhosis represents an important unmet segment, with several development programs evaluating therapies in F4 disease or portal-hypertension-related populations. A second opportunity is combination therapy, in which agents acting on liver fibrosis or de novo lipogenesis could potentially be paired with established or emerging metabolic therapies. In parallel, RNAi programs targeting HSD17B13, PNPLA3 and CIDEB introduce a genetically informed therapeutic strategy that may eventually create new treatment segments beyond conventional receptor agonists and metabolic small molecules. These approaches increase the possibility that future MASH treatment will become stratified by fibrosis stage, metabolic phenotype and molecular mechanism.
Challenges
The main industry challenge is demonstrating durable differentiation in a rapidly expanding pipeline. Future candidates will increasingly be compared not only on MASH resolution or fibrosis improvement, but also on cardiometabolic benefits, safety, tolerability, route of administration and suitability for chronic therapy. Developers must also address the commercial difficulty of translating clinical-trial eligibility into routine diagnosis and treatment, particularly when patients are managed across multiple specialties. For clinical-stage companies, increasingly large late-stage studies and confirmatory requirements raise development costs and financing demands, while the arrival of approved therapies raises the efficacy and convenience benchmarks that new entrants must meet.
Industry Chain Analysis
The MASH Drug industry chain begins with pharmaceutical raw materials, active pharmaceutical ingredients, specialty intermediates and modality-specific manufacturing technologies. Small-molecule programs depend on chemical synthesis and formulation capabilities, while peptide and protein therapies require biologic or peptide production systems, and RNA/oligonucleotide therapies require sequence design, oligonucleotide synthesis, conjugation and liver-targeted delivery technologies. In the midstream, value creation is concentrated in target validation, candidate selection, clinical development, fibrosis and metabolic endpoint demonstration, regulatory approval, scale-up manufacturing and lifecycle management. Because MASH is a chronic disease with heterogeneous metabolic and fibrotic characteristics, the ability to generate evidence across both liver-specific and cardiometabolic outcomes is becoming increasingly valuable. Downstream commercialization involves hepatology and gastroenterology practices, metabolic and obesity-care networks, specialty pharmacy channels and healthcare systems. Market value therefore depends not only on drug efficacy, but also on patient identification, fibrosis staging, reimbursement access, treatment persistence and the ability to integrate therapy into multidisciplinary chronic-disease management.
Segment Insights
By mechanism, THR-? agonists and GLP-1 receptor agonists currently represent the most commercially advanced MASH Drug segments because each class now has an FDA-approved therapy for moderate-to-advanced fibrosis. Beyond these categories, the pipeline remains highly diversified. FGF21 analogs, GLP-1/glucagon dual receptor agonists and pan-PPAR agonists are positioned around combined liver and metabolic effects, while FASN inhibitors and galectin-3 inhibitors focus more directly on pathways associated with lipid synthesis, fibrogenesis or advanced disease. RNA and oligonucleotide approaches provide an additional mechanism layer through genetically linked targets.
From a product-form perspective, oral therapies have an important convenience advantage for long-term chronic management, while injectable peptide/protein drugs can leverage strong metabolic efficacy and established treatment behavior in obesity and diabetes. From a development-status perspective, approved MASH drugs currently represent a relatively concentrated segment, whereas investigational candidates remain much broader in both mechanism and modality. From a patient perspective, F2-F3 noncirrhotic MASH is the principal commercial treatment segment today, while F4 compensated cirrhosis is becoming one of the most strategically important development areas.
Downstream Market Opportunities
The downstream opportunity is increasingly defined by patient phenotype rather than liver disease alone. Patients with F2-F3 fibrosis remain the core pharmacological treatment population, but MASH patients with obesity or type 2 diabetes create a particularly important overlap between hepatology and metabolic medicine. Therapies capable of addressing liver disease together with weight, glycemic or broader cardiometabolic risk factors may therefore have advantages in multidisciplinary treatment pathways. At the other end of the disease spectrum, patients with compensated cirrhosis represent a high-unmet-need population and an important extension opportunity for antifibrotic, metabolic and combination approaches if ongoing development programs establish sufficient clinical benefit.
Regional Insights
North America is currently the most commercially advanced MASH Drug region. The United States established the first dedicated pharmacological treatment market with FDA approval of Rezdiffra in March 2024 and subsequently broadened mechanism choice through approval of Wegovy for MASH in August 2025. This early regulatory transition has placed the U.S. at the center of initial physician adoption, patient-identification practices and commercial access development.
Europe entered the commercialization stage after Rezdiffra received conditional European Union marketing authorization in August 2025, with rollout occurring on a country-by-country basis. The regional market is therefore moving from clinical development toward commercial access, although reimbursement structures and launch timing can vary across countries. In other regions, future market development will depend more strongly on local regulatory approvals, fibrosis-diagnosis capacity, reimbursement systems and the ability to identify high-risk patients within large obesity and type 2 diabetes populations.
Competitive Landscape Analysis
The competitive landscape is shifting from a single-product market toward a layered structure combining commercial products, late-stage metabolic therapies, liver-targeted small molecules and genetically directed treatments. Madrigal Pharmaceuticals established the first-mover position with Rezdiffra, while Novo Nordisk introduced a GLP-1-based treatment route through Wegovy. Roche is building a late-stage FGF21 position around pegozafermin, and Boehringer Ingelheim, Inventiva and Altimmune are advancing survodutide, lanifibranor and pemvidutide through late-stage development. Viking Therapeutics provides additional THR-? competition through VK2809, while Alnylam Pharmaceuticals and Regeneron Pharmaceuticals are pursuing gene-silencing programs against HSD17B13, PNPLA3 and CIDEB. Galectin Therapeutics is differentiated by its focus on belapectin for MASH cirrhosis and portal hypertension, whereas Sagimet Biosciences is developing the FASN inhibitor denifanstat and exploring combination development with resmetirom. The strategic direction of competition is therefore moving beyond simple entry into MASH toward mechanism differentiation, fibrosis-stage expansion, metabolic benefit and potential combination positioning.
Report Scope
LPI (LP Information)' newest research report, the “MASH Drug Industry Forecast” looks at past sales and reviews total world MASH Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected MASH Drug sales for 2026 through 2032. With MASH Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world MASH Drug industry.
This Insight Report provides a comprehensive analysis of the global MASH Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on MASH Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global MASH Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for MASH Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global MASH Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of MASH Drug market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- THR-? Agonists
- GLP-1 Receptor Agonists
- Other
Segmentation by Drug Classification:
- Small Molecule Drugs
- Peptide and Protein Drugs
Segmentation by Route of Administration:
- Oral Drugs
- Subcutaneous Injectable Drugs
- Intravenous Injectable Drugs
Segmentation by Application:
- MASH with Compensated Cirrhosis (F4)
- MASH with Obesity
- MASH with Type 2 Diabetes
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Madrigal Pharmaceuticals
- Roche
- Boehringer Ingelheim
- Inventiva
- Viking Therapeutics
- Altimmune
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Galectin Therapeutics
- Sagimet Biosciences
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global MASH Drug Market Size (2021-2032)
2.1.2 MASH Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for MASH Drug by Country/Region (2021, 2025 & 2032)
2.2 MASH Drug Segment by Type
2.2.1 THR-? Agonists
2.2.2 GLP-1 Receptor Agonists
2.2.3 Other
2.2.4 MASH Drug Market Size by Type
2.2.4.1 MASH Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global MASH Drug Market Size Market Share by Type (2021-2026)
2.3 MASH Drug Segment by Drug Classification
2.3.1 Small Molecule Drugs
2.3.2 Peptide and Protein Drugs
2.3.3 MASH Drug Market Size by Drug Classification
2.3.3.1 MASH Drug Market Size CAGR by Drug Classification (2021 VS 2025 VS 2032)
2.3.3.2 Global MASH Drug Market Size Market Share by Drug Classification (2021-2026)
2.4 MASH Drug Segment by Route of Administration
2.4.1 Oral Drugs
2.4.2 Subcutaneous Injectable Drugs
2.4.3 Intravenous Injectable Drugs
2.4.4 MASH Drug Market Size by Route of Administration
2.4.4.1 MASH Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global MASH Drug Market Size Market Share by Route of Administration (2021-2026)
2.5 MASH Drug Segment by Application
2.5.1 MASH with Compensated Cirrhosis (F4)
2.5.2 MASH with Obesity
2.5.3 MASH with Type 2 Diabetes
2.5.4 MASH Drug Market Size by Application
2.5.4.1 MASH Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global MASH Drug Market Size Market Share by Application (2021-2026)
3 MASH DRUG MARKET SIZE BY PLAYER
3.1 MASH Drug Market Size Market Share by Player
3.1.1 Global MASH Drug Revenue by Player (2021-2026)
3.1.2 Global MASH Drug Revenue Market Share by Player (2021-2026)
3.2 Global MASH Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MASH DRUG BY REGION
4.1 MASH Drug Market Size by Region (2021-2026)
4.2 Global MASH Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas MASH Drug Market Size Growth (2021-2026)
4.4 APAC MASH Drug Market Size Growth (2021-2026)
4.5 Europe MASH Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa MASH Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas MASH Drug Market Size by Country (2021-2026)
5.2 Americas MASH Drug Market Size by Type (2021-2026)
5.3 Americas MASH Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MASH Drug Market Size by Region (2021-2026)
6.2 APAC MASH Drug Market Size by Type (2021-2026)
6.3 APAC MASH Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe MASH Drug Market Size by Country (2021-2026)
7.2 Europe MASH Drug Market Size by Type (2021-2026)
7.3 Europe MASH Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa MASH Drug by Region (2021-2026)
8.2 Middle East & Africa MASH Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa MASH Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MASH DRUG MARKET FORECAST
10.1 Global MASH Drug Forecast by Region (2027-2032)
10.1.1 Global MASH Drug Forecast by Region (2027-2032)
10.1.2 Americas MASH Drug Forecast
10.1.3 APAC MASH Drug Forecast
10.1.4 Europe MASH Drug Forecast
10.1.5 Middle East & Africa MASH Drug Forecast
10.2 Americas MASH Drug Forecast by Country (2027-2032)
10.2.1 United States Market MASH Drug Forecast
10.2.2 Canada Market MASH Drug Forecast
10.2.3 Mexico Market MASH Drug Forecast
10.2.4 Brazil Market MASH Drug Forecast
10.3 APAC MASH Drug Forecast by Region (2027-2032)
10.3.1 China MASH Drug Market Forecast
10.3.2 Japan Market MASH Drug Forecast
10.3.3 Korea Market MASH Drug Forecast
10.3.4 Southeast Asia Market MASH Drug Forecast
10.3.5 India Market MASH Drug Forecast
10.3.6 Australia Market MASH Drug Forecast
10.4 Europe MASH Drug Forecast by Country (2027-2032)
10.4.1 Germany Market MASH Drug Forecast
10.4.2 France Market MASH Drug Forecast
10.4.3 UK Market MASH Drug Forecast
10.4.4 Italy Market MASH Drug Forecast
10.4.5 Russia Market MASH Drug Forecast
10.5 Middle East & Africa MASH Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market MASH Drug Forecast
10.5.2 South Africa Market MASH Drug Forecast
10.5.3 Israel Market MASH Drug Forecast
10.5.4 Turkey Market MASH Drug Forecast
10.6 Global MASH Drug Forecast by Type (2027-2032)
10.7 Global MASH Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market MASH Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk MASH Drug Product Offered
11.1.3 Novo Nordisk MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Madrigal Pharmaceuticals
11.2.1 Madrigal Pharmaceuticals Company Information
11.2.2 Madrigal Pharmaceuticals MASH Drug Product Offered
11.2.3 Madrigal Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Madrigal Pharmaceuticals Main Business Overview
11.2.5 Madrigal Pharmaceuticals Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche MASH Drug Product Offered
11.3.3 Roche MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Information
11.4.2 Boehringer Ingelheim MASH Drug Product Offered
11.4.3 Boehringer Ingelheim MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Boehringer Ingelheim Main Business Overview
11.4.5 Boehringer Ingelheim Latest Developments
11.5 Inventiva
11.5.1 Inventiva Company Information
11.5.2 Inventiva MASH Drug Product Offered
11.5.3 Inventiva MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Inventiva Main Business Overview
11.5.5 Inventiva Latest Developments
11.6 Viking Therapeutics
11.6.1 Viking Therapeutics Company Information
11.6.2 Viking Therapeutics MASH Drug Product Offered
11.6.3 Viking Therapeutics MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Viking Therapeutics Main Business Overview
11.6.5 Viking Therapeutics Latest Developments
11.7 Altimmune
11.7.1 Altimmune Company Information
11.7.2 Altimmune MASH Drug Product Offered
11.7.3 Altimmune MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Altimmune Main Business Overview
11.7.5 Altimmune Latest Developments
11.8 Alnylam Pharmaceuticals
11.8.1 Alnylam Pharmaceuticals Company Information
11.8.2 Alnylam Pharmaceuticals MASH Drug Product Offered
11.8.3 Alnylam Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Alnylam Pharmaceuticals Main Business Overview
11.8.5 Alnylam Pharmaceuticals Latest Developments
11.9 Regeneron Pharmaceuticals
11.9.1 Regeneron Pharmaceuticals Company Information
11.9.2 Regeneron Pharmaceuticals MASH Drug Product Offered
11.9.3 Regeneron Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Regeneron Pharmaceuticals Main Business Overview
11.9.5 Regeneron Pharmaceuticals Latest Developments
11.10 Galectin Therapeutics
11.10.1 Galectin Therapeutics Company Information
11.10.2 Galectin Therapeutics MASH Drug Product Offered
11.10.3 Galectin Therapeutics MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Galectin Therapeutics Main Business Overview
11.10.5 Galectin Therapeutics Latest Developments
11.11 Sagimet Biosciences
11.11.1 Sagimet Biosciences Company Information
11.11.2 Sagimet Biosciences MASH Drug Product Offered
11.11.3 Sagimet Biosciences MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Sagimet Biosciences Main Business Overview
11.11.5 Sagimet Biosciences Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global MASH Drug Market Size (2021-2032)
2.1.2 MASH Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for MASH Drug by Country/Region (2021, 2025 & 2032)
2.2 MASH Drug Segment by Type
2.2.1 THR-? Agonists
2.2.2 GLP-1 Receptor Agonists
2.2.3 Other
2.2.4 MASH Drug Market Size by Type
2.2.4.1 MASH Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global MASH Drug Market Size Market Share by Type (2021-2026)
2.3 MASH Drug Segment by Drug Classification
2.3.1 Small Molecule Drugs
2.3.2 Peptide and Protein Drugs
2.3.3 MASH Drug Market Size by Drug Classification
2.3.3.1 MASH Drug Market Size CAGR by Drug Classification (2021 VS 2025 VS 2032)
2.3.3.2 Global MASH Drug Market Size Market Share by Drug Classification (2021-2026)
2.4 MASH Drug Segment by Route of Administration
2.4.1 Oral Drugs
2.4.2 Subcutaneous Injectable Drugs
2.4.3 Intravenous Injectable Drugs
2.4.4 MASH Drug Market Size by Route of Administration
2.4.4.1 MASH Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global MASH Drug Market Size Market Share by Route of Administration (2021-2026)
2.5 MASH Drug Segment by Application
2.5.1 MASH with Compensated Cirrhosis (F4)
2.5.2 MASH with Obesity
2.5.3 MASH with Type 2 Diabetes
2.5.4 MASH Drug Market Size by Application
2.5.4.1 MASH Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global MASH Drug Market Size Market Share by Application (2021-2026)
3 MASH DRUG MARKET SIZE BY PLAYER
3.1 MASH Drug Market Size Market Share by Player
3.1.1 Global MASH Drug Revenue by Player (2021-2026)
3.1.2 Global MASH Drug Revenue Market Share by Player (2021-2026)
3.2 Global MASH Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MASH DRUG BY REGION
4.1 MASH Drug Market Size by Region (2021-2026)
4.2 Global MASH Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas MASH Drug Market Size Growth (2021-2026)
4.4 APAC MASH Drug Market Size Growth (2021-2026)
4.5 Europe MASH Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa MASH Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas MASH Drug Market Size by Country (2021-2026)
5.2 Americas MASH Drug Market Size by Type (2021-2026)
5.3 Americas MASH Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MASH Drug Market Size by Region (2021-2026)
6.2 APAC MASH Drug Market Size by Type (2021-2026)
6.3 APAC MASH Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe MASH Drug Market Size by Country (2021-2026)
7.2 Europe MASH Drug Market Size by Type (2021-2026)
7.3 Europe MASH Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa MASH Drug by Region (2021-2026)
8.2 Middle East & Africa MASH Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa MASH Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MASH DRUG MARKET FORECAST
10.1 Global MASH Drug Forecast by Region (2027-2032)
10.1.1 Global MASH Drug Forecast by Region (2027-2032)
10.1.2 Americas MASH Drug Forecast
10.1.3 APAC MASH Drug Forecast
10.1.4 Europe MASH Drug Forecast
10.1.5 Middle East & Africa MASH Drug Forecast
10.2 Americas MASH Drug Forecast by Country (2027-2032)
10.2.1 United States Market MASH Drug Forecast
10.2.2 Canada Market MASH Drug Forecast
10.2.3 Mexico Market MASH Drug Forecast
10.2.4 Brazil Market MASH Drug Forecast
10.3 APAC MASH Drug Forecast by Region (2027-2032)
10.3.1 China MASH Drug Market Forecast
10.3.2 Japan Market MASH Drug Forecast
10.3.3 Korea Market MASH Drug Forecast
10.3.4 Southeast Asia Market MASH Drug Forecast
10.3.5 India Market MASH Drug Forecast
10.3.6 Australia Market MASH Drug Forecast
10.4 Europe MASH Drug Forecast by Country (2027-2032)
10.4.1 Germany Market MASH Drug Forecast
10.4.2 France Market MASH Drug Forecast
10.4.3 UK Market MASH Drug Forecast
10.4.4 Italy Market MASH Drug Forecast
10.4.5 Russia Market MASH Drug Forecast
10.5 Middle East & Africa MASH Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market MASH Drug Forecast
10.5.2 South Africa Market MASH Drug Forecast
10.5.3 Israel Market MASH Drug Forecast
10.5.4 Turkey Market MASH Drug Forecast
10.6 Global MASH Drug Forecast by Type (2027-2032)
10.7 Global MASH Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market MASH Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk MASH Drug Product Offered
11.1.3 Novo Nordisk MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Madrigal Pharmaceuticals
11.2.1 Madrigal Pharmaceuticals Company Information
11.2.2 Madrigal Pharmaceuticals MASH Drug Product Offered
11.2.3 Madrigal Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Madrigal Pharmaceuticals Main Business Overview
11.2.5 Madrigal Pharmaceuticals Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche MASH Drug Product Offered
11.3.3 Roche MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Information
11.4.2 Boehringer Ingelheim MASH Drug Product Offered
11.4.3 Boehringer Ingelheim MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Boehringer Ingelheim Main Business Overview
11.4.5 Boehringer Ingelheim Latest Developments
11.5 Inventiva
11.5.1 Inventiva Company Information
11.5.2 Inventiva MASH Drug Product Offered
11.5.3 Inventiva MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Inventiva Main Business Overview
11.5.5 Inventiva Latest Developments
11.6 Viking Therapeutics
11.6.1 Viking Therapeutics Company Information
11.6.2 Viking Therapeutics MASH Drug Product Offered
11.6.3 Viking Therapeutics MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Viking Therapeutics Main Business Overview
11.6.5 Viking Therapeutics Latest Developments
11.7 Altimmune
11.7.1 Altimmune Company Information
11.7.2 Altimmune MASH Drug Product Offered
11.7.3 Altimmune MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Altimmune Main Business Overview
11.7.5 Altimmune Latest Developments
11.8 Alnylam Pharmaceuticals
11.8.1 Alnylam Pharmaceuticals Company Information
11.8.2 Alnylam Pharmaceuticals MASH Drug Product Offered
11.8.3 Alnylam Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Alnylam Pharmaceuticals Main Business Overview
11.8.5 Alnylam Pharmaceuticals Latest Developments
11.9 Regeneron Pharmaceuticals
11.9.1 Regeneron Pharmaceuticals Company Information
11.9.2 Regeneron Pharmaceuticals MASH Drug Product Offered
11.9.3 Regeneron Pharmaceuticals MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Regeneron Pharmaceuticals Main Business Overview
11.9.5 Regeneron Pharmaceuticals Latest Developments
11.10 Galectin Therapeutics
11.10.1 Galectin Therapeutics Company Information
11.10.2 Galectin Therapeutics MASH Drug Product Offered
11.10.3 Galectin Therapeutics MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Galectin Therapeutics Main Business Overview
11.10.5 Galectin Therapeutics Latest Developments
11.11 Sagimet Biosciences
11.11.1 Sagimet Biosciences Company Information
11.11.2 Sagimet Biosciences MASH Drug Product Offered
11.11.3 Sagimet Biosciences MASH Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Sagimet Biosciences Main Business Overview
11.11.5 Sagimet Biosciences Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. MASH Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. MASH Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of THR-? Agonists
Table 4. Major Players of GLP-1 Receptor Agonists
Table 5. Major Players of Other
Table 6. MASH Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global MASH Drug Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Small Molecule Drugs
Table 10. Major Players of Peptide and Protein Drugs
Table 11. MASH Drug Market Size CAGR by Drug Classification (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global MASH Drug Market Size by Drug Classification (2021-2026) & ($ millions)
Table 13. Global MASH Drug Market Size Market Share by Drug Classification (2021-2026)
Table 14. Major Players of Oral Drugs
Table 15. Major Players of Subcutaneous Injectable Drugs
Table 16. Major Players of Intravenous Injectable Drugs
Table 17. MASH Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global MASH Drug Market Size by Route of Administration (2021-2026) & ($ millions)
Table 19. Global MASH Drug Market Size Market Share by Route of Administration (2021-2026)
Table 20. MASH Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 22. Global MASH Drug Market Size Market Share by Application (2021-2026)
Table 23. Global MASH Drug Revenue by Player (2021-2026) & ($ millions)
Table 24. Global MASH Drug Revenue Market Share by Player (2021-2026)
Table 25. MASH Drug Key Players Head office and Products Offered
Table 26. MASH Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 30. Global MASH Drug Market Size Market Share by Region (2021-2026)
Table 31. Global MASH Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global MASH Drug Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas MASH Drug Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas MASH Drug Market Size Market Share by Country (2021-2026)
Table 35. Americas MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas MASH Drug Market Size Market Share by Type (2021-2026)
Table 37. Americas MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas MASH Drug Market Size Market Share by Application (2021-2026)
Table 39. APAC MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC MASH Drug Market Size Market Share by Region (2021-2026)
Table 41. APAC MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe MASH Drug Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe MASH Drug Market Size Market Share by Country (2021-2026)
Table 45. Europe MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of MASH Drug
Table 51. Key Market Challenges & Risks of MASH Drug
Table 52. Key Industry Trends of MASH Drug
Table 53. Global MASH Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global MASH Drug Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global MASH Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global MASH Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novo Nordisk Details, Company Type, MASH Drug Area Served and Its Competitors
Table 58. Novo Nordisk MASH Drug Product Offered
Table 59. Novo Nordisk MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novo Nordisk Main Business
Table 61. Novo Nordisk Latest Developments
Table 62. Madrigal Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 63. Madrigal Pharmaceuticals MASH Drug Product Offered
Table 64. Madrigal Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Madrigal Pharmaceuticals Main Business
Table 66. Madrigal Pharmaceuticals Latest Developments
Table 67. Roche Details, Company Type, MASH Drug Area Served and Its Competitors
Table 68. Roche MASH Drug Product Offered
Table 69. Roche MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Roche Main Business
Table 71. Roche Latest Developments
Table 72. Boehringer Ingelheim Details, Company Type, MASH Drug Area Served and Its Competitors
Table 73. Boehringer Ingelheim MASH Drug Product Offered
Table 74. Boehringer Ingelheim MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Boehringer Ingelheim Main Business
Table 76. Boehringer Ingelheim Latest Developments
Table 77. Inventiva Details, Company Type, MASH Drug Area Served and Its Competitors
Table 78. Inventiva MASH Drug Product Offered
Table 79. Inventiva MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Inventiva Main Business
Table 81. Inventiva Latest Developments
Table 82. Viking Therapeutics Details, Company Type, MASH Drug Area Served and Its Competitors
Table 83. Viking Therapeutics MASH Drug Product Offered
Table 84. Viking Therapeutics MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Viking Therapeutics Main Business
Table 86. Viking Therapeutics Latest Developments
Table 87. Altimmune Details, Company Type, MASH Drug Area Served and Its Competitors
Table 88. Altimmune MASH Drug Product Offered
Table 89. Altimmune MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Altimmune Main Business
Table 91. Altimmune Latest Developments
Table 92. Alnylam Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 93. Alnylam Pharmaceuticals MASH Drug Product Offered
Table 94. Alnylam Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Alnylam Pharmaceuticals Main Business
Table 96. Alnylam Pharmaceuticals Latest Developments
Table 97. Regeneron Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 98. Regeneron Pharmaceuticals MASH Drug Product Offered
Table 99. Regeneron Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Regeneron Pharmaceuticals Main Business
Table 101. Regeneron Pharmaceuticals Latest Developments
Table 102. Galectin Therapeutics Details, Company Type, MASH Drug Area Served and Its Competitors
Table 103. Galectin Therapeutics MASH Drug Product Offered
Table 104. Galectin Therapeutics MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Galectin Therapeutics Main Business
Table 106. Galectin Therapeutics Latest Developments
Table 107. Sagimet Biosciences Details, Company Type, MASH Drug Area Served and Its Competitors
Table 108. Sagimet Biosciences MASH Drug Product Offered
Table 109. Sagimet Biosciences MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Sagimet Biosciences Main Business
Table 111. Sagimet Biosciences Latest Developments
Table 1. MASH Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. MASH Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of THR-? Agonists
Table 4. Major Players of GLP-1 Receptor Agonists
Table 5. Major Players of Other
Table 6. MASH Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global MASH Drug Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Small Molecule Drugs
Table 10. Major Players of Peptide and Protein Drugs
Table 11. MASH Drug Market Size CAGR by Drug Classification (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global MASH Drug Market Size by Drug Classification (2021-2026) & ($ millions)
Table 13. Global MASH Drug Market Size Market Share by Drug Classification (2021-2026)
Table 14. Major Players of Oral Drugs
Table 15. Major Players of Subcutaneous Injectable Drugs
Table 16. Major Players of Intravenous Injectable Drugs
Table 17. MASH Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global MASH Drug Market Size by Route of Administration (2021-2026) & ($ millions)
Table 19. Global MASH Drug Market Size Market Share by Route of Administration (2021-2026)
Table 20. MASH Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 22. Global MASH Drug Market Size Market Share by Application (2021-2026)
Table 23. Global MASH Drug Revenue by Player (2021-2026) & ($ millions)
Table 24. Global MASH Drug Revenue Market Share by Player (2021-2026)
Table 25. MASH Drug Key Players Head office and Products Offered
Table 26. MASH Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 30. Global MASH Drug Market Size Market Share by Region (2021-2026)
Table 31. Global MASH Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global MASH Drug Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas MASH Drug Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas MASH Drug Market Size Market Share by Country (2021-2026)
Table 35. Americas MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas MASH Drug Market Size Market Share by Type (2021-2026)
Table 37. Americas MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas MASH Drug Market Size Market Share by Application (2021-2026)
Table 39. APAC MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC MASH Drug Market Size Market Share by Region (2021-2026)
Table 41. APAC MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe MASH Drug Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe MASH Drug Market Size Market Share by Country (2021-2026)
Table 45. Europe MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa MASH Drug Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa MASH Drug Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa MASH Drug Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of MASH Drug
Table 51. Key Market Challenges & Risks of MASH Drug
Table 52. Key Industry Trends of MASH Drug
Table 53. Global MASH Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global MASH Drug Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global MASH Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global MASH Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novo Nordisk Details, Company Type, MASH Drug Area Served and Its Competitors
Table 58. Novo Nordisk MASH Drug Product Offered
Table 59. Novo Nordisk MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novo Nordisk Main Business
Table 61. Novo Nordisk Latest Developments
Table 62. Madrigal Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 63. Madrigal Pharmaceuticals MASH Drug Product Offered
Table 64. Madrigal Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Madrigal Pharmaceuticals Main Business
Table 66. Madrigal Pharmaceuticals Latest Developments
Table 67. Roche Details, Company Type, MASH Drug Area Served and Its Competitors
Table 68. Roche MASH Drug Product Offered
Table 69. Roche MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Roche Main Business
Table 71. Roche Latest Developments
Table 72. Boehringer Ingelheim Details, Company Type, MASH Drug Area Served and Its Competitors
Table 73. Boehringer Ingelheim MASH Drug Product Offered
Table 74. Boehringer Ingelheim MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Boehringer Ingelheim Main Business
Table 76. Boehringer Ingelheim Latest Developments
Table 77. Inventiva Details, Company Type, MASH Drug Area Served and Its Competitors
Table 78. Inventiva MASH Drug Product Offered
Table 79. Inventiva MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Inventiva Main Business
Table 81. Inventiva Latest Developments
Table 82. Viking Therapeutics Details, Company Type, MASH Drug Area Served and Its Competitors
Table 83. Viking Therapeutics MASH Drug Product Offered
Table 84. Viking Therapeutics MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Viking Therapeutics Main Business
Table 86. Viking Therapeutics Latest Developments
Table 87. Altimmune Details, Company Type, MASH Drug Area Served and Its Competitors
Table 88. Altimmune MASH Drug Product Offered
Table 89. Altimmune MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Altimmune Main Business
Table 91. Altimmune Latest Developments
Table 92. Alnylam Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 93. Alnylam Pharmaceuticals MASH Drug Product Offered
Table 94. Alnylam Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Alnylam Pharmaceuticals Main Business
Table 96. Alnylam Pharmaceuticals Latest Developments
Table 97. Regeneron Pharmaceuticals Details, Company Type, MASH Drug Area Served and Its Competitors
Table 98. Regeneron Pharmaceuticals MASH Drug Product Offered
Table 99. Regeneron Pharmaceuticals MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Regeneron Pharmaceuticals Main Business
Table 101. Regeneron Pharmaceuticals Latest Developments
Table 102. Galectin Therapeutics Details, Company Type, MASH Drug Area Served and Its Competitors
Table 103. Galectin Therapeutics MASH Drug Product Offered
Table 104. Galectin Therapeutics MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Galectin Therapeutics Main Business
Table 106. Galectin Therapeutics Latest Developments
Table 107. Sagimet Biosciences Details, Company Type, MASH Drug Area Served and Its Competitors
Table 108. Sagimet Biosciences MASH Drug Product Offered
Table 109. Sagimet Biosciences MASH Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Sagimet Biosciences Main Business
Table 111. Sagimet Biosciences Latest Developments
LIST OF FIGURES
Figure 1. MASH Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global MASH Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. MASH Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. MASH Drug Sales Market Share by Country/Region (2025)
Figure 8. MASH Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global MASH Drug Market Size Market Share by Type in 2025
Figure 10. Global MASH Drug Market Size Market Share by Drug Classification in 2025
Figure 11. Global MASH Drug Market Size Market Share by Route of Administration in 2025
Figure 12. MASH Drug in MASH with Compensated Cirrhosis (F4)
Figure 13. Global MASH Drug Market: MASH with Compensated Cirrhosis (F4) (2021-2026) & ($ millions)
Figure 14. MASH Drug in MASH with Obesity
Figure 15. Global MASH Drug Market: MASH with Obesity (2021-2026) & ($ millions)
Figure 16. MASH Drug in MASH with Type 2 Diabetes
Figure 17. Global MASH Drug Market: MASH with Type 2 Diabetes (2021-2026) & ($ millions)
Figure 18. Global MASH Drug Market Size Market Share by Application in 2025
Figure 19. Global MASH Drug Revenue Market Share by Player in 2025
Figure 20. Global MASH Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas MASH Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC MASH Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe MASH Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa MASH Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas MASH Drug Value Market Share by Country in 2025
Figure 26. United States MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC MASH Drug Market Size Market Share by Region in 2025
Figure 31. APAC MASH Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC MASH Drug Market Size Market Share by Application (2021-2026)
Figure 33. China MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe MASH Drug Market Size Market Share by Country in 2025
Figure 40. Europe MASH Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe MASH Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa MASH Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa MASH Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa MASH Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas MASH Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC MASH Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe MASH Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa MASH Drug Market Size 2027-2032 ($ millions)
Figure 59. United States MASH Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada MASH Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico MASH Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil MASH Drug Market Size 2027-2032 ($ millions)
Figure 63. China MASH Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan MASH Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea MASH Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia MASH Drug Market Size 2027-2032 ($ millions)
Figure 67. India MASH Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia MASH Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany MASH Drug Market Size 2027-2032 ($ millions)
Figure 70. France MASH Drug Market Size 2027-2032 ($ millions)
Figure 71. UK MASH Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy MASH Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia MASH Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt MASH Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa MASH Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel MASH Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey MASH Drug Market Size 2027-2032 ($ millions)
Figure 78. Global MASH Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global MASH Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries MASH Drug Market Size 2027-2032 ($ millions)
Figure 1. MASH Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global MASH Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. MASH Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. MASH Drug Sales Market Share by Country/Region (2025)
Figure 8. MASH Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global MASH Drug Market Size Market Share by Type in 2025
Figure 10. Global MASH Drug Market Size Market Share by Drug Classification in 2025
Figure 11. Global MASH Drug Market Size Market Share by Route of Administration in 2025
Figure 12. MASH Drug in MASH with Compensated Cirrhosis (F4)
Figure 13. Global MASH Drug Market: MASH with Compensated Cirrhosis (F4) (2021-2026) & ($ millions)
Figure 14. MASH Drug in MASH with Obesity
Figure 15. Global MASH Drug Market: MASH with Obesity (2021-2026) & ($ millions)
Figure 16. MASH Drug in MASH with Type 2 Diabetes
Figure 17. Global MASH Drug Market: MASH with Type 2 Diabetes (2021-2026) & ($ millions)
Figure 18. Global MASH Drug Market Size Market Share by Application in 2025
Figure 19. Global MASH Drug Revenue Market Share by Player in 2025
Figure 20. Global MASH Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas MASH Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC MASH Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe MASH Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa MASH Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas MASH Drug Value Market Share by Country in 2025
Figure 26. United States MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC MASH Drug Market Size Market Share by Region in 2025
Figure 31. APAC MASH Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC MASH Drug Market Size Market Share by Application (2021-2026)
Figure 33. China MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe MASH Drug Market Size Market Share by Country in 2025
Figure 40. Europe MASH Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe MASH Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa MASH Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa MASH Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa MASH Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries MASH Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas MASH Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC MASH Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe MASH Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa MASH Drug Market Size 2027-2032 ($ millions)
Figure 59. United States MASH Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada MASH Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico MASH Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil MASH Drug Market Size 2027-2032 ($ millions)
Figure 63. China MASH Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan MASH Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea MASH Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia MASH Drug Market Size 2027-2032 ($ millions)
Figure 67. India MASH Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia MASH Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany MASH Drug Market Size 2027-2032 ($ millions)
Figure 70. France MASH Drug Market Size 2027-2032 ($ millions)
Figure 71. UK MASH Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy MASH Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia MASH Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt MASH Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa MASH Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel MASH Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey MASH Drug Market Size 2027-2032 ($ millions)
Figure 78. Global MASH Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global MASH Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries MASH Drug Market Size 2027-2032 ($ millions)
